Monaco vs Sri Lanka: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Monaco
0.0%
in 2025
Sri Lanka
0.0%
in 2025
Monaco rank
165th
Sri Lanka rank
165th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Monaco
- Sri Lanka
How they compare
Monaco currently reports 0.0% against 0.0% in Sri Lanka, a difference of 0.0%.
Across all 18 years both countries report, Sri Lanka has been ahead every year.
Monaco ranks 165th and Sri Lanka ranks 165th of 192 countries.
Head to head by decade
| Decade | Monaco | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 0.0% | 0.0% | 0.0% | — |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Monaco or Sri Lanka?
- Monaco, at 0.0% against 0.0% in Sri Lanka as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Monaco and Sri Lanka?
- 0.0%, with Monaco ahead.
- How many years of comparable data are there for Monaco and Sri Lanka?
- 18 years are reported by both, from 2008 to 2025.
- How do Monaco and Sri Lanka rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Monaco ranks 165th and Sri Lanka ranks 165th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.